Harrow Inc (HROW) Stock Price, Quote & News

Company Profile

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract sur...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 615 733 4730

Website: www.harrow.com

Address:

1A Burton Hills Boulevard, Suite 200, Nashville, United States

Finnish_boy Aug. 3 at 9:18 AM

$HROW 1 week time to buy the stock

0 · Reply

AMP19 Aug. 3 at 1:00 AM

$HROW what do folks have the DED market at in US? Xiidra did 400m in 2024 as biggest? Restasis did 200m? Rest of market 900m?

0 · Reply

kshonstocks Aug. 2 at 6:57 PM

Very discouraging to see $HROW lose the 50 dma, may be caught up in the Trump admin is after big pharma storm....

1 · Reply

Finnish_boy Aug. 2 at 7:19 AM

$HROW That excitement

1 · Reply

Finnish_boy Aug. 1 at 10:44 PM

$HROW

1 · Reply

Finnish_boy Aug. 1 at 10:31 PM

$HROW RXs growth of VEVYE/IHEEZO will be amazing in Q2. Not sure about how much Iheezo and Vevye ASP down. But assuming 70-75m revenue for Q2 is logical and reasonable. SP will hit $50 this month! I really buy more next week. I had to talk about new data bc i want to earn extra profits. Now i stop posting for a while

3 · Reply

Finnish_boy Aug. 1 at 10:15 PM

$HROW The data is from bloomberg and i guess that it's trailing 4 week. According this data VEVYE revenue likely around 30 million. If data is missing a lot of RXs, then 35-40m is possible. Q2 will be over 70m and FY25 total over 310m imho. I will buy more on next week!

2 · Reply

Finnish_boy Aug. 1 at 9:14 PM

$HROW This data looks amazing. Can be that it's also trailing 4 week and data underestimates. But look at miebo.. it has been around 75k during Q2. BLCO reported weekly TRx about 25k. Looking at Cequa feels like it's rather 4 week trailing. I dont know

0 · Reply

Finnish_boy Aug. 1 at 8:40 PM

$HROW How this data is possible? They stop reporting PhilRX data? This looks like trailing 3 week data. Equals avg. 15k weekly TRX during 3 week period. ???? What am i missing. Otherwise this is super bullish.

1 · Reply

HROWfan Aug. 1 at 5:42 PM

$HROW https://x.com/Michigan_Value/status/1951302797208453533

2 · Reply

Harrow To Report Second Quarter 2025 Financial Results After Market Close on August 11, 2025

Jul 17, 2025, 7:00 AM EDT - 17 days ago

Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States

Jul 17, 2025, 7:00 AM EDT - 17 days ago

Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States

Jul 15, 2025, 10:38 AM EDT - 18 days ago

HROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law Firm

Jul 11, 2025, 5:47 PM EDT - 22 days ago

Harrow's Internal $100 Price Target Is Ambitious, But New Bloomberg Data Backs It Up

Jul 9, 2025, 2:52 PM EDT - 24 days ago

Harrow: Immense Upside Potential

Jun 18, 2025, 7:00 AM EDT - 6 weeks ago

Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications

Jun 13, 2025, 8:30 AM EDT - 7 weeks ago

I Am Swimming In Dividends With +7% Yields

UMH

Jun 9, 2025, 7:00 AM EDT - 7 weeks ago

Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

May 28, 2025, 3:20 PM EDT - 2 months ago

Harrow: Epic Growth & Operating Leverage On Full Display

May 14, 2025, 7:00 AM EDT - 2 months ago

Harrow to Present at Two Investor Conferences in May

May 10, 2025, 6:17 PM EDT - 3 months ago

Harrow, Inc. (HROW) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:01 PM EDT - 3 months ago

Harrow Announces First-Quarter 2025 Financial Results

May 5, 2025, 7:00 AM EDT - 3 months ago

Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025

Apr 24, 2025, 10:00 AM EDT - 3 months ago

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC.

Apr 10, 2025, 7:00 AM EDT - 4 months ago

Harrow Expands VEVYE® Access for All Program to ImprimisRx's Klarity-C Patients

Mar 29, 2025, 4:30 PM EDT - 4 months ago

Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade)

Mar 28, 2025, 2:00 PM EDT - 4 months ago

Harrow, Inc. (HROW) Q4 2024 Earnings Conference Call

Mar 28, 2025, 1:39 PM EDT - 4 months ago

Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings Ramp

Mar 27, 2025, 4:01 PM EDT - 4 months ago

Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results

Mar 27, 2025, 10:45 AM EDT - 4 months ago

Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025

Mar 24, 2025, 7:00 AM EDT - 4 months ago

Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL

Mar 17, 2025, 4:01 PM EDT - 4 months ago

Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance

Mar 17, 2025, 7:00 AM EDT - 4 months ago

Harrow Launches VEVYE® Access for All

Mar 11, 2025, 7:00 AM EDT - 5 months ago

Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE®

Mar 3, 2025, 7:15 AM EST - 5 months ago

Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025

Mar 1, 2025, 8:50 AM EST - 5 months ago

Smallcap Eyecare Pharma Company Harrow Health Has Two Major Catalysts For 2025

Jan 27, 2025, 7:30 AM EST - 6 months ago

Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients

COR

Jan 7, 2025, 7:00 AM EST - 7 months ago

Harrow Appoints Amir H. Shojaei as Chief Scientific Officer

Jan 3, 2025, 3:43 PM EST - 7 months ago

Those Derisked Baby Bonds Of Harrow, Inc.

Dec 14, 2024, 12:09 AM EST - 8 months ago

Harrow: The Triesence Relaunch

Nov 21, 2024, 7:00 AM EST - 9 months ago

Harrow's ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.

Nov 15, 2024, 7:00 AM EST - 9 months ago

Harrow Announces Participation in Upcoming Investor Conferences

Nov 14, 2024, 2:56 PM EST - 9 months ago

Harrow, Inc. (HROW) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 4:34 PM EST - 9 months ago

Harrow Announces Third Quarter 2024 Financial Results

Nov 13, 2024, 7:00 AM EST - 9 months ago

Harrow Launches Access and Affordability Program with Price Reductions for Branded Products

GDRX

Nov 12, 2024, 7:00 AM EST - 9 months ago

Harrow Announces Market Access Wins for VEVYE®

Nov 11, 2024, 6:37 AM EST - 9 months ago

Harrow: VEVYE And Its Impact On The DED Market

Nov 7, 2024, 7:00 AM EST - 9 months ago

Harrow Partners with Asembia to Enhance Provider and Patient Experience Through Nationwide Digital Services and Hub Support for Harrow's Branded Eyecare Products

Oct 31, 2024, 7:00 AM EDT - 9 months ago

Harrow To Report Third Quarter 2024 Financial Results After Market Close on November 13, 2024

Oct 12, 2024, 10:30 AM EDT - 10 months ago

I Am Banking On The Silver Tsunami With Big Dividends

THQ XOMA

Oct 3, 2024, 7:00 AM EDT - 10 months ago

Harrow Relaunches TRIESENCE®

Oct 2, 2024, 12:10 PM EDT - 10 months ago

Harrow Inc (HROW) Shares Up 3.26% on Oct 2

Sep 25, 2024, 12:02 PM EDT - 11 months ago

Harrow Announces Nashville Expansion

Sep 3, 2024, 7:00 AM EDT - 11 months ago

Harrow to Present at Three Investor Conferences in September in New York

Aug 16, 2024, 3:42 PM EDT - 1 year ago

Harrow: Bulls On Parade

Aug 7, 2024, 4:01 PM EDT - 1 year ago

Harrow Announces Second Quarter 2024 Financial Results

Finnish_boy Aug. 3 at 9:18 AM

$HROW 1 week time to buy the stock

0 · Reply

AMP19 Aug. 3 at 1:00 AM

$HROW what do folks have the DED market at in US? Xiidra did 400m in 2024 as biggest? Restasis did 200m? Rest of market 900m?

0 · Reply

kshonstocks Aug. 2 at 6:57 PM

Very discouraging to see $HROW lose the 50 dma, may be caught up in the Trump admin is after big pharma storm....

1 · Reply

Finnish_boy Aug. 2 at 7:19 AM

$HROW That excitement

1 · Reply

Finnish_boy Aug. 1 at 10:44 PM

$HROW

1 · Reply

Finnish_boy Aug. 1 at 10:31 PM

3 · Reply

Finnish_boy Aug. 1 at 10:15 PM

2 · Reply

Finnish_boy Aug. 1 at 9:14 PM

0 · Reply

Finnish_boy Aug. 1 at 8:40 PM

1 · Reply

HROWfan Aug. 1 at 5:42 PM

$HROW https://x.com/Michigan_Value/status/1951302797208453533

2 · Reply

Fullback Aug. 1 at 4:44 PM

$HROW Hmmmm, holding the $31 level for now.

0 · Reply

ACNY555 Aug. 1 at 1:28 PM

$HROW we are in the hands of the market sadly and job numbers etc. Talking to an advocate of IRS. Mentioned how they got rid of 4500 of tax payer service employees. But the catch they just put an announcement to hire 3500 LOL ...So u get rid of 4500 experience and let them sit at home getting paid for 6months to now announce 3500 that will need training. The government is a mess.

0 · Reply

Fullback Aug. 1 at 11:06 AM

$HROW TA folks, what is strong support? $30?

2 · Reply

Finnish_boy Aug. 1 at 8:04 AM

$HROW Remember buy the dip.. SP hits $50 in August. my last post for a while, i am back on earnings day pumping the stock.. have a great weekend! Tryptyr post comments:

2 · Reply

Finnish_boy Aug. 1 at 7:56 AM

$HROW Markets sleeping on vevye.. load up all you can under $30. If not dropping there, load up anyways

1 · Reply

Finnish_boy Aug. 1 at 7:32 AM

$HROW I might hit the jackpot.. indexes taking a breath, all my stocks going down but i transfer money to HROW.. then HROW jumps +40% and i buy back my other stocks when they are lower than now. Then indexes will have strong Q4 and all my stocks skyrocketing.

0 · Reply

Finnish_boy Aug. 1 at 6:01 AM

$HROW "So I’m on day 2 of trying tryptyr and let me just say it’s burns sooooo bad putting it in . I can’t even see for the first 2 minutes." If Reproxalap approved, it will have horrible reception.

1 · Reply

Finnish_boy Aug. 1 at 5:12 AM

$HROW The article is actually amazing summary. We have a case where we win crazy lot money, or a lot money if the risks happens. That's why i am very fine with these risks.

1 · Reply

Finnish_boy Jul. 31 at 9:44 PM

$HROW When the bloomberg data was out, i was afraid that i cant buy anymore under $40 levels.. now i'm super happy wheb i can load up cheaper before Q2 report. I'm pretty sure that after Q2 report stock jumps up a lot.. i think over $45 after the report and SP hits $50 levels in August. Markets offer amazing buying opportunity again when healtcare sector is volatile. Lets goo. Selling under $50 is not clever. And SP hits $100 next year. https://mvcinvesting.substack.com/p/three-small-caps-im-watching-part

2 · Reply

Fullback Jul. 31 at 9:42 PM

$HROW Put/Call = ~.42, <1 considered Bullish.

1 · Reply

Fullback Jul. 31 at 8:29 PM

$HROW In Options land, the 1-16-26 $50 call has the largest open interest, followed by the 8-15-25 $40 call.

0 · Reply

Fullback Jul. 31 at 8:14 PM

$HROW ~500k Volume, a tad above avg. Trend is down heading into earnings. I don't feel like this will reverse, it may level off, but I don't see a big swing back to the $36 level. My $34 and $35 level buys have triggered a 7% decline threshold forcing me to sell these positions. If trend continues, I'll probably load up on 8-11. I still believe SP will have a positive reaction to earnings.

1 · Reply

Market Cap	1.15B
Revenue (ttm)	199.61M
Net Income (ttm)	-17.48M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	244.31
Profit Margin	-8.76%
Debt to Equity Ratio	2.01

Volume	530,600
Avg Vol	434,728
Day's Range	N/A - N/A
Shares Out	36.69M
Stochastic %K	15%
Beta	0.41
Analysts	Strong Sell
Price Target	$60.60